Kestra (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

Original reporting
Published Sep 15, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 3:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Kestra (KMTS) Q1 2027 Earnings Call Transcript — source image
Decision brief

The 30-second read

$KMTSNeutralMed
01

Why it matters

The earnings beat and guidance raise expectations for market share gains, but widening losses may limit upside.

02

Market read

Earnings release provides fresh data for traders; guidance lift may influence short-term price action.

03

What to watch

Potential reimbursement risk if payer coverage changes; AI roadmap execution timeline uncertain.

Relevance 7/10Novelty 8/10Timing: post-earnings release today

Background

Kestra Medical Technologies reported Q1 2027 results, showing rapid revenue expansion and updated FY guidance.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Q1 2027 earnings released with 60% revenue growth and raised FY revenue guidance to $141M, new guidance impacting valuation.

Expected impact

Potential modest upside if market focuses on revenue beat; downside risk from higher loss guidance.

Evidence & confidence

Revenue beat is significant for a small-cap medtech, but expanding losses and higher expense guidance temper enthusiasm.

Market effects

Highlights growth in the wearable cardioverter defibrillator market, may boost peers in cardiac device space.

U.S. medtech sector could see increased investor interest following guidance lift.

Limited to U.S. investors; foreign markets unlikely to be affected.

Counterpoint

Higher operating losses and expense guidance could outweigh revenue growth, leading to price weakness.

Key entities

  • Kestra Medical Technologies

    NASDAQ-listed medtech firm specializing in wearable cardioverter defibrillators.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.